Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Affiliations

• ¹ Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
• ² Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
• ³ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
• ⁴ Department of Hematology, Jewish General Hospital, Montreal, QC, Canada.
• ⁵ Hematology-Oncology, Hôpital Saint-Louis, Paris, France.
• ⁶ Division of Cancer Sciences, The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
• ⁷ DITEP, Insitut Gustave Roussy, Villejuif, France.
• ⁸ Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.
• ⁹ Hematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
• ¹⁰ Hematology and Oncology, Fujita Health University School of Medicine, Toyoake, Japan.
• ¹¹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany.
• ¹² Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA, USA.
• ¹³ Medical Oncology, Merck & Co., Inc, Kenilworth, NJ, USA.
• ¹⁴ Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.